220 related articles for article (PubMed ID: 23934050)
21. Biosimilars in psoriasis: what can we expect?
Radtke MA; Augustin M
J Dtsch Dermatol Ges; 2014 Apr; 12(4):306-12. PubMed ID: 24698590
[TBL] [Abstract][Full Text] [Related]
22. From bioequivalence to biosimilars: How much do regulators dare?
Weise M
Z Evid Fortbild Qual Gesundhwes; 2019 Mar; 140():58-62. PubMed ID: 30622000
[TBL] [Abstract][Full Text] [Related]
23. Biosimilar insulins: a European perspective.
DeVries JH; Gough SC; Kiljanski J; Heinemann L
Diabetes Obes Metab; 2015 May; 17(5):445-51. PubMed ID: 25376600
[TBL] [Abstract][Full Text] [Related]
24. [Biosimilars, no generic biologicals!].
Knuts B
J Pharm Belg; 2016 Dec; (4):24-29. PubMed ID: 30281245
[TBL] [Abstract][Full Text] [Related]
25. Biosimilar safety considerations in clinical practice.
Choy E; Jacobs IA
Semin Oncol; 2014 Feb; 41 Suppl 1():S3-14. PubMed ID: 24560025
[TBL] [Abstract][Full Text] [Related]
26. Biosimilars: A consideration of the regulations in the United States and European union.
Daller J
Regul Toxicol Pharmacol; 2016 Apr; 76():199-208. PubMed ID: 26732800
[TBL] [Abstract][Full Text] [Related]
27. [Biosimilars: opportunities and risks].
Grieshaber-Bouyer R; Lorenz HM
Internist (Berl); 2020 May; 61(5):522-529. PubMed ID: 32333085
[TBL] [Abstract][Full Text] [Related]
28. Biosimilar drugs : concerns and opportunities.
Genazzani AA; Biggio G; Caputi AP; Del Tacca M; Drago F; Fantozzi R; Canonico PL
BioDrugs; 2007; 21(6):351-6. PubMed ID: 18020619
[TBL] [Abstract][Full Text] [Related]
29. Regulation of biosimilar medicines and current perspectives on interchangeability and policy.
O'Callaghan J; Barry SP; Bermingham M; Morris JM; Griffin BT
Eur J Clin Pharmacol; 2019 Jan; 75(1):1-11. PubMed ID: 30187103
[TBL] [Abstract][Full Text] [Related]
30. Considerations related to comparative clinical studies for biosimilars.
Rathore AS; Stevenson JG; Chhabra H
Expert Opin Drug Saf; 2021 Mar; 20(3):265-274. PubMed ID: 33455482
[No Abstract] [Full Text] [Related]
31. Biosimilars in Dermatology: Current Situation (Part I).
Puig L; Carretero G; Daudén E; Ferrándiz C; Marrón SE; Martorell A; Pérez-Suárez B; Rodriguez-Cerdeira C; Ruiz-Villaverde R; Sánchez-Carazo JL; Velasco M;
Actas Dermosifiliogr; 2015 Sep; 106(7):545-9. PubMed ID: 25987472
[TBL] [Abstract][Full Text] [Related]
32. Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology.
Mysler E; Pineda C; Horiuchi T; Singh E; Mahgoub E; Coindreau J; Jacobs I
Rheumatol Int; 2016 May; 36(5):613-25. PubMed ID: 26920148
[TBL] [Abstract][Full Text] [Related]
33. Clinical evidence supporting the marketing authorization of biosimilars in Europe.
Allocati E; Bertele' V; Gerardi C; Garattini S; Banzi R
Eur J Clin Pharmacol; 2020 Apr; 76(4):557-566. PubMed ID: 31897530
[TBL] [Abstract][Full Text] [Related]
34. Worldwide experience with biosimilar development.
McCamish M; Woollett G
MAbs; 2011; 3(2):209-17. PubMed ID: 21441787
[TBL] [Abstract][Full Text] [Related]
35. Japanese regulation of biosimilar products: past experience and current challenges.
Arato T
Br J Clin Pharmacol; 2016 Jul; 82(1):30-40. PubMed ID: 26987746
[TBL] [Abstract][Full Text] [Related]
36. Biosimilars in Developed and Developing East and Southeast Asian Countries: Japan, South Korea, and Malaysia-Overview, Evolution, and Regulations Assessment.
Bas TG; Oliu Castillo C
Biomed Res Int; 2016; 2016():5910403. PubMed ID: 27213153
[TBL] [Abstract][Full Text] [Related]
37. Development and regulation of biosimilars: current status and future challenges.
Tsiftsoglou AS; Ruiz S; Schneider CK
BioDrugs; 2013 Jun; 27(3):203-11. PubMed ID: 23553340
[TBL] [Abstract][Full Text] [Related]
38. The regulatory framework of biosimilars in the European Union.
Minghetti P; Rocco P; Cilurzo F; Vecchio LD; Locatelli F
Drug Discov Today; 2012 Jan; 17(1-2):63-70. PubMed ID: 21856438
[TBL] [Abstract][Full Text] [Related]
39. Global regulatory standards for the approval of biosimilars.
Mounho B; Phillips A; Holcombe K; Grampp G; Lubiniecki T; Mollerup I; Jones C
Food Drug Law J; 2010; 65(4):819-37, ii-iii. PubMed ID: 24479248
[TBL] [Abstract][Full Text] [Related]
40. Iraqi regulatory authority current system and experience with biosimilars.
Al-Kinani KK; Ibrahim MJ; Al-Zubaidi RF; Younus MM; Ramadhan SH; Kadhim HJ; Challand R
Regul Toxicol Pharmacol; 2020 Nov; 117():104768. PubMed ID: 32861742
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
